Issue link: https://viewer.e-digitaledition.com/i/1062971
"Omalizumab is a medication specifi cally designed to block the allergy antibody, immunoglobulin E (IgE), which is a small molecule that begins the process of an allergic reaction," says Carla McGuire Dav i s , M D, Ch ief of t he S ec t ion of Immunology, Allergy and Rheumatology in the Department of Pediatrics at Baylor College of Medicine. "The drug stops the a llergic reaction from happening for patients who have a high level of IgE in their blood." A f t er nu merou s s t ud ies det a i led the protective effects of oma lizumab during OIT, the Nationa l Institutes of Health funded a phase 2 clinical trial to further explore the drug. The results of the double-blind, randomized, controlled tria l were published recently in T he Lancet Gastroenterology & Hepatology. Approximately 50 children with mul- tiple food allergies received omalizumab or a placebo for 16 weeks. "At the eight-week ma rk, we intro- duced two to f ive culprit food a llergens in a n OIT prog ra m," says study author Sha ron Chinthraja h, MD, Director of t he Clinica l Tra nslationa l Resea rch Un it a t t he S e a n N. Pa rker C ent er for A l lerg y a nd A st h ma Resea rch at Sta nford. "At 36 weeks, we looked for t he abi l it y of pa r t icipa nt s t o pa ss a food cha llenge." Participants received two grams of protein from each of their two or more food allergens. "To put two grams in perspective, that's about half a tablespoon of peanut butter or a quarter cup of milk," Dr. Chinthrajah says. "For those who are particularly sensi- tive to even a minute amount of food, this is quite a signifi cant change." PROMISING RESULTS At t he end of t he s t udy, 8 3 percent of t he 36 pa r ticipa nts who received omalizumab passed the challenge for two foods. Results were similar for partici- pants who passed the challenge for three foods (81 percent of 26 participants) or more (76 percent of 17 participants). By compa rison, on ly 33 percent of the 12 participants in the placebo group passed the food challenge for two foods, and there were even fewer for three foods: 29 percent of seven participants. None of the fi ve participants in the placebo group with four or more food a llergies passed the food cha llenge for a ll trigger foods. The study also found that cross-desen- sitization could be achieved with OIT. All patients who were a llergic to wa lnuts and pecans passed food cha llenges for both a f ter receiving a n OIT reg imen that included wa lnut. Over 80 percent of pa r ticipa nts with both cashew a nd pistachio a llerg ies achieved the sa me result when given only cashews as pa r t of their reg imen. O n l y e x p e c t e d m i n o r a d v e r s e reactions occurred during the study. About one in f ive pa r ticipa nts in the oma lizumab group had gastrointestina l reactions, compa red w ith 54 percent in the placebo g roup. No pa r ticipa nts e x p er ien c e d m ajor r e a c t ion s s uc h as a naphyla xis. " The best ti me per iod to exa m i ne a d v e r s e e v e nt s w a s w e e k e i g ht t o week 16," says a not her aut hor of t he study, A ma nda Rudma n Spergel, MD, Medical Officer at the National Institute of A llerg y a nd Infectious Diseases. "If participants were considered treatment fa i lu res at week 17, t hey were g iven open-label oma lizumab." The researchers are pursuing further phase 2 tria ls to determine if sustained unresponsiveness to food a llergens can be achieved through OIT. " The results of the study were dra- matic a nd tel l us t hat a la rger st udy needs to be done to see whet her t he results ca n be replicated," Dr. Rudma n Spergel says. " The la rger study could ta ke t he end poi nt a lit t le fa r t her so t hat we ca n see how t o rea l ly apply t h is for patient s w it h food a l lerg ies [ long-term]." n M D N E W S . C O M /// M D N E W S C l E V E l A N D /A K R O N / C A N T O N ■ N O V E M B E R / D E C E M B E R 2 018 1 3

